IL-KANG NA

Group leader BCRT / Charité: platform immune system
Therapy-induced Remodelling in Immuno-Oncology

Scientific Development/ CV:

2007-2009	Postdoctoral Research Fellow, Memorial Sloan-Kettering Cancer Center (Prof. M. van den Brink)
2009	Principle Investigator at the BCRT and Experimental and Clinical Research Center
2011	Habilitation in Experimental Medicine, Charité – Universitätsmedizin Berlin: “Migration of T cells and Tumor cells”
2013/15	Board exams for Internal medicine and Hematology/Oncology
2017	W2 Professorship for Therapy-induced Remodeling in Immuno-Oncology and senior physician at the Hem/Onc Department
2019	Speaker of the Graduate school “Berlin school of Integrative Oncology (BSIO)”

Expertise:

Immune dynamics and dysregulations in cancer patients, Cell therapy, Immune reconstitution post therapy

Relevant Projects/ Highlights:

Determination of functional immune alterations derived from longitudinal monitoring to define response stratifiers for immune checkpoint inhibitor treatment, ongoing
Longitudinal plasticity of T cells in allogeneic hematopoietic stem cell transplantation (CITEseq), ongoing
Multi-organ-chip in lymphoma, ongoing
Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges. **Int J Cancer**, 2021
A comparative analysis of human bone marrow-resident and peripheral memory B cells. ***J Allergy Clin Immunol***, 2018
A transgenic dual-luciferase reporter mouse for longitudinal and functional monitoring of T cells in vivo. ***Cancer Immunol Res***, 2018
Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT. ***Blood***, 2014
The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. ***J Clin Invest***, 2010

Funding

Deutsche Krebshilfe, BIH, Else-Kröner-Stfitung, Wilhelm-Sander-Stiftung, DKMS, DFG, Industry (Takeda, BMS, Octapharma)..

IL-KANG NA

Group leader BCRT / Charité: platform immune system
Therapy-induced Remodelling in Immuno-Oncology

Aims for the BCRT

- Support the further development of the BCRT into an (immunological) translational hub
- Act as a connecting link between lab and patients
- Act as a connecting link between cancer therapy and regeneration as well as tumor and immune system
- Establish next-generation patient staging pipelines - Integration of longitudinal omics-analyses in medical practice
- Focus on refined translation to improve patient stratification
- Engage PhD and MD students at an early stage of their career in a collaborative dialogue to merge MD and PhD
  worlds to train more translational thinking and to plan projects with clinical impact

Overarching topics

- Longitudinal cancer/ immune dynamics and alterations triggered by treatment
- TCR clonotype dynamics in cell therapy
- Secondary immunodeficiency